Gardiquimod

• Description :

  Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs) . Gardiquimod specifically activates TLR7 at concentrations below 10 μM.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Toll-like Receptor (TLR)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/gardiquimod.html

• Concentration :

  10mM

• Purity :

  99.91

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  OC(C)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N

• Molecular Formula :

  C17H23N5O

• Molecular Weight :

  313.40

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29 (6) :907-18.|[2]Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369 (2) :298-306.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HIV-1; TLR7; TLR8

• CAS Number :

  [1020412-43-4]